中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.016 seconds)

    METHODS OF TREATING DRY EYE DISEASE USING TNF ALPHA ANTAGONISTS
    2.
    发明申请
    METHODS OF TREATING DRY EYE DISEASE USING TNF ALPHA ANTAGONISTS 有权

    公开(公告)号：US20250129414A1

    公开(公告)日：2025-04-24

    申请号：US18921747

    申请日：2024-10-21

    Applicant: NOVARTIS AG

    Inventor： Yunsheng He ,  Christian Leisner ,  Michael Wald ,  Georges Weissgerber

    IPC: C12Q1/6858 ,  A61K38/00 ,  A61P27/02 ,  C07K16/24 ,  C12Q1/6827 ,  C12Q1/6883

    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNFα antagonist, e.g., a TNFα antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNFα antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNFα antagonist, e.g., a TNFα antibody, such as LME636.

    METHODS OF TREATING DRY EYE DISEASE USING TNF ALPHA ANTAGONISTS
    6.
    发明申请
    METHODS OF TREATING DRY EYE DISEASE USING TNF ALPHA ANTAGONISTS 审中-公开

    公开(公告)号：US20190177407A1

    公开(公告)日：2019-06-13

    申请号：US16311001

    申请日：2017-06-19

    Applicant: NOVARTIS AG

    Inventor： Yunsheng He ,  Christian Leisner ,  Michael Wald ,  Georges Weissberber

    IPC: C07K16/24 ,  A61P27/02 ,  C12Q1/6827 ,  C12Q1/6858

    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNFα antagonist, e.g., a TNFα antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNFα antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNFα antagonist, e.g., a TNFα antibody, such as LME636.

Patent Agency Ranking